Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Medtronic ( (MDT) ).
On September 29, 2025, Medtronic, Inc., a subsidiary of Medtronic plc, issued €1.5 billion in senior notes, with maturities in 2030 and 2045, to refinance existing debts. The issuance is expected to strengthen Medtronic’s financial position by repaying Medtronic Luxco’s senior notes due in 2025, and the notes have been approved for listing on the New York Stock Exchange, indicating a strategic financial maneuver to optimize debt management.
The most recent analyst rating on (MDT) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Medtronic stock, see the MDT Stock Forecast page.
Spark’s Take on MDT Stock
According to Spark, TipRanks’ AI Analyst, MDT is a Outperform.
Medtronic’s overall stock score of 80 reflects strong financial performance and positive earnings call sentiment, supported by strategic corporate events. While the valuation is on the higher side, the company’s robust growth prospects and stable technical indicators contribute to a favorable outlook.
To see Spark’s full report on MDT stock, click here.
More about Medtronic
Medtronic is a leading company in the medical technology industry, primarily focused on developing and manufacturing medical devices and therapies. Its market focus includes providing innovative solutions for various medical conditions, aiming to improve patient outcomes globally.
Average Trading Volume: 7,242,942
Technical Sentiment Signal: Buy
Current Market Cap: $120.9B
For a thorough assessment of MDT stock, go to TipRanks’ Stock Analysis page.